A new microbicide built from two types of RNA has shown promise against HIV in lab experiments, but moving it toward becoming a marketable product is proving difficult. Alan Dove investigates what's interfering with this novel therapeutic RNA strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dove, A. An apt approach. Nat Med 16, 258–260 (2010). https://doi.org/10.1038/nm0310-258
Issue Date:
DOI: https://doi.org/10.1038/nm0310-258